Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCD mutant FGF1
- Development stage
- Preclinical
- Lead developer
- Celon Pharma
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
BCD mutant FGF1 (also known as FGF1HSBCD) is an engineered recombinant human fibroblast growth factor 1 (FGF1) analogue developed by Celon Pharma in collaboration with the University of Wrocław and the University of Warmia and Mazury. It is designed as a potential therapy for type 2 diabetes and related metabolic disorders. The BCD mutant incorporates three point mutations (S116R, S17K, and L72R, designated B, C, and D respectively) that enhance its affinity for heparin and heparan sulfate proteoglycans (HSPGs) while significantly reducing its mitogenic (pro-proliferative) activity. In preclinical models of type 2 diabetes, BCD mutant FGF1 demonstrated robust, sustained glucose-lowering efficacy without inducing hypoglycemia, offering a safer profile compared to wild-type FGF1.
- Other names
- FGF1 BCDFGF-1 BCDFGF 1 BCDFGF1 BCD mutantFGF-1 BCD mutantFGF 1 BCD mutantfibroblast growth factor 1 BCD mutant
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))
Beyond the preview
Go deeper on BCD mutant FGF1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCD mutant FGF1.